Beijing Biostar Pharmaceuticals Company Description

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research and development, production, and commercialization of oncology products in the People’s Republic of China.

The company develops Utidelone injection, a microtubule inhibitor for the treatment of metastasis breast cancer, advanced non-small cell lung cancer, solid tumor, and Glioblastoma.

It also engages in the development of Utidelone oral capsule that is in phase II/III clinical trials; Utidelone nano formulation; and Utidelone antibody drug conjugate, as well as other active pharmaceutical ingredients, such as BG22, BG18 and BG44.

The company was incorporated in 2002 and is based in Beijing, China.

Beijing Biostar Pharmaceuticals Co., Ltd.

Country	China
Founded	2002
Industry	Biological Products, Except Diagnostic Substances
CEO	Rongguo Qiu

Contact Details

Address: Tower B, Yicheng Fortune Center Beijing, 100176 China
Phone	86 10 6786 4938
Website	biostar-pharm.com

Stock Details

Ticker Symbol	2563
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100006NB3
SIC Code	2836

Key Executives

Name	Position
Rongguo Qiu	Chief Executive Officer
Fei Peng	Chief Financial Officer
Xin Chen	Chief Operating Officer